SARS-CoV-2: its potential neurological manifestations and plausible mechanism: a review article

被引:0
作者
Tasneem Taher
Anum Bilal Sheikh
Farah Anwar
Faisal Khosa
机构
[1] Dow University of Health Sciences,Department of Internal Medicine
[2] University of British Columbia,Department of Radiology
来源
Acta Neurologica Belgica | 2021年 / 121卷
关键词
Nervous system; COVID-19; CNS; PNS; Coronavirus; Pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Coronavirus disease (COVID-19) was first identified in late December 2019. The disease began in Wuhan, Hubei province in China and since then it has spread quickly to many countries all over the world. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was majorly seen to overwhelm the respiratory system with mild to severe acute respiratory syndrome considered pathognomic for the disease. However, with time a plethora of symptoms was observed in the patients infected with COVID-19 including strong evidence for neurological symptoms. Evidence suggests that the virus has both central and peripheral nervous system manifestations. Patients, particularly those who suffer from a severe illness, have a central nervous system (CNS) involvement and neurological manifestations. There is precise and targeted documentation of neurological symptoms with details of clinical, neurological, and electrophysiological findings. This review article thus gives an insight into the neuro-invasive potential of COVID-19 and discusses the possible pathogenesis.
引用
收藏
页码:331 / 339
页数:8
相关论文
共 50 条
  • [31] Genomic surveillance of SARS-CoV-2 in patients presenting neurological manifestations
    Vicco, Anna
    Caccuri, Francesca
    Messali, Serena
    Vitiello, Adriana
    Emmi, Aron
    Del Vecchio, Claudia
    Reale, Alberto
    Caruso, Arnaldo
    Ottaviano, Giancarlo
    Mucignat, Carla
    Parolin, Cristina
    Antonini, Angelo
    Calistri, Arianna
    PLOS ONE, 2022, 17 (06):
  • [32] Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2
    Joy D. Iroegbu
    Chibuzor W. Ifenatuoha
    Omamuyovwi M. Ijomone
    Neurological Sciences, 2020, 41 : 1329 - 1337
  • [33] Extrapulmonary Manifestations of SARS-CoV-2 A Brief Review
    Osorio, Maria F.
    Vaca, Richard G.
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2020, 28 (04) : 196 - 199
  • [34] Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2
    Iroegbu, Joy D.
    Ifenatuoha, Chibuzor W.
    Ijomone, Omamuyovwi M.
    NEUROLOGICAL SCIENCES, 2020, 41 (06) : 1329 - 1337
  • [35] Neurological infection and complications of SARS-CoV-2: A review
    Singh, Santosh
    Meher, Nikita
    Mohammed, Arifullah
    Razab, Mohammad Khairul Azhar Abdul
    Bhaskar, L. V. K. S.
    Nawi, Norazlina Mat
    MEDICINE, 2023, 102 (05) : E30284
  • [36] A Comprehensive Review of Neurodegenerative Manifestations of SARS-CoV-2
    Bedran, Dominika
    Bedran, Georges
    Kote, Sachin
    VACCINES, 2024, 12 (03)
  • [37] Mechanistic Episodes on SARS-CoV-2 Mediated Neurological Manifestations and Their Possible Therapeutic Interventions
    Nida, Sobia
    Srinivisan, Hemalatha
    Pandurangan, Ashok Kumar
    Waseem, Mohammad
    JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2022, 41 (01) : 85 - 98
  • [38] A Systematic Review of Severe Neurological Manifestations in Pediatric Patients with Coexisting SARS-CoV-2 Infection
    O'Loughlin, Lauren
    Toledo, Nilo Alvarez
    Budrie, Leon
    Waechter, Randall
    Rayner, Joanna
    NEUROLOGY INTERNATIONAL, 2021, 13 (03): : 410 - 427
  • [39] Neurologic Manifestations and Complications of SARS-CoV-2 Infection A Narrative Review
    Del Brutto, Oscar
    Costa, Aldo F.
    Aguayo, Xavier
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2020, 28 (05) : 272 - 276
  • [40] Crosstalk between SARS-CoV-2 Infection and Neurological Disorders: A Review
    Azhar, Asim
    Wali, Mohammad Akram
    Rashid, Qudsia
    Khan, Wajihul Hasan
    Al-hosaini, Khaled
    Owais, Mohammad
    Kamal, Mohammad Amjad
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2023, 22 (05) : 643 - 658